Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AGTR2 | P50052 | 10/20 | 0.57 |
| ▸ | AGTR1 | P30556 | 2/20 | 0.45 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.42 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8964420 | 1.00 | AGTR2 (0.57) | AGTR2AGTR1SCN9APDE4D | |
| SCHEMBL421422 | 0.89 | AGTR2 (0.56) | AGTR2AGTR1 | |
| SCHEMBL433767 | 0.89 | AGTR2 (0.56) | AGTR2AGTR1 | |
| SCHEMBL21881389 | 0.89 | AGTR2 (0.51) | AGTR2AGTR1SCN9APDE4D | |
| Hydrochloric Acid SCHEMBL23780714 | 0.88 | AGTR2 (0.55) | AGTR2AGTR1 | |
| Hydrochloric Acid SCHEMBL23780713 | 0.88 | AGTR2 (0.55) | AGTR2AGTR1 | |
| SCHEMBL10072201 | 0.86 | CNR2 (0.43) | AGTR2AGTR1 | |
| SCHEMBL21602377 | 0.81 | AGTR2 (0.52) | AGTR2AGTR1 | |
| Hydrochloric Acid SCHEMBL28510044 | 0.80 | AGTR2 (0.51) | AGTR2AGTR1 | |
| Hydrochloric Acid SCHEMBL29758873 | 0.80 | AGTR2 (0.51) | AGTR2AGTR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5489686-A | CARDIOVASCULAR DISORDER, NERVOUS SYSTEM DISORDER, ANTIDIURETIC , PSYCHLOGICAL DISORDER, ANTIDEPRESSANTS | WARNER-LAMBERT COMPANY (US) | 1996-02-06 | — | — | US | claimed |
| EP-0641326-A1 | SUBSTITUTED 1,2,3,4-TETRAHYDROISOQUINOLINES WITH ANGIOTENSIN II RECEPTOR ANTAGONIST PROPERTIES | WARNER-LAMBERT COMPANY (US) | 1995-03-08 | — | — | EP | claimed |
| WO-1993023378-A1 | SUBSTITUTED 1,2,3,4-TETRAHYDROISOQUINOLINES WITH ANGIOTENSIN II RECEPTOR ANTAGONIST PROPERTIES | WARNER-LAMBERT COMPANY (US) | 1993-11-25 | — | — | WO | claimed |
| US-5525614-A | TREATING VASCULAR RESTENOSIS, CNS DISORDERS | WARNER-LAMBERT COMPANY (US) | 1996-06-11 | — | — | US | disclosed |
| US-5489686-A | CARDIOVASCULAR DISORDER, NERVOUS SYSTEM DISORDER, ANTIDIURETIC , PSYCHLOGICAL DISORDER, ANTIDEPRESSANTS | WARNER-LAMBERT COMPANY (US) | 1996-02-06 | — | — | US | disclosed |
| EP-0641326-A1 | SUBSTITUTED 1,2,3,4-TETRAHYDROISOQUINOLINES WITH ANGIOTENSIN II RECEPTOR ANTAGONIST PROPERTIES | WARNER-LAMBERT COMPANY (US) | 1995-03-08 | — | — | EP | disclosed |
| US-5350757-A | Treatment of vascular restenosis, nervous system disorders and cognition enhancement | WARNER-LAMBERT COMPANY (US) | 1994-09-27 | — | — | US | disclosed |
| WO-1993023378-A1 | SUBSTITUTED 1,2,3,4-TETRAHYDROISOQUINOLINES WITH ANGIOTENSIN II RECEPTOR ANTAGONIST PROPERTIES | WARNER-LAMBERT COMPANY (US) | 1993-11-25 | — | — | WO | disclosed |
| US-5246943-A | Substituted 1,2,3,4-tetahydroisoquinolines with angiotensin II receptor antagonist properties | WARNER-LAMBERT COMPANY (US) | 1993-09-21 | — | — | US | disclosed |